← Leaderboards
Alejandro Soto-Gutierrez
Massachusetts General Hospital
$6,883,976
Attributed
$11,755,981
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,858,153 · 11
By mechanism
R01$4,722,961 · 2
U2C$3,548,996 · 2
UH3$2,306,928 · 1
UG3$1,540,594 · 1
P30$934,492 · 2
R24$917,443 · 1
Top collaborators
- D. Lansing Taylor7 shared
- Jaideep Behari5 shared
- Mark T. Miedel4 shared
- Deepak Nagrath4 shared
- David A Geller2 shared
- Satdarshan Singh Monga2 shared
- Mark E Schurdak2 shared
- Lawrence A Vernetti2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Schahram Akbarian$48,610,378
- Mehmet Toner$56,861,630
- Ralph Weissleder$110,468,710
- David E Fisher$28,420,496
- Xu Yu$21,799,579
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverCellsHepatocyteCell TypeMetabolicFutureLiver DiseasesInnovationNonalcoholic SteatohepatitisPhenotypeFatty LiverFibrosisInduced Pluripotent Stem CellEnvironmentOrganTechnologySuccessNon-Alcoholic Fatty Liver DiseasePrimary Carcinoma Of The Liver CellsCirrhosisLiver FunctionGeneticAnimal ModelAdult
Grant awards (32)
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,540,258
U2C · FY2025 · TR
Implementing A QSP Platform to Predict and Test Drugs for Metabolic Associated Fatty Liver Disease Genetic Variants in an iPSC-cell Based Human Biomimetic Liver Microphysiology System$598,763
R01 · FY2025 · DK
Human Liver Tissue & Hepatocytes Research Resource (HLTHRR)$421,554
R24 · FY2025 · DK
Administrative Core$193,219
U2C · FY2025 · TR · contact PI
Human Synthetic Liver Biology Core$185,695
P30 · FY2025 · DK · contact PI
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,561,914
U2C · FY2024 · TR
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$777,501
UH3 · FY2024 · TR
Implementing A QSP Platform to Predict and Test Drugs for Metabolic Associated Fatty Liver Disease Genetic Variants in an iPSC-cell Based Human Biomimetic Liver Microphysiology System$695,586
R01 · FY2024 · DK
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$506,236
R01 · FY2024 · DK · contact PI
Human Liver Tissue & Hepatocytes Research Resource (HLTHRR)$495,889
R24 · FY2024 · DK
Administrative Core$253,605
U2C · FY2024 · TR · contact PI
Human Synthetic Liver Biology Core$185,695
P30 · FY2024 · DK · contact PI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$762,142
UH3 · FY2023 · TR
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$527,329
R01 · FY2023 · DK · contact PI
Human Synthetic Liver Biology Core$188,407
P30 · FY2023 · DK · contact PI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$767,285
UH3 · FY2022 · TR
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$526,476
R01 · FY2022 · DK · contact PI
Human Synthetic Liver Biology Core$186,288
P30 · FY2022 · DK · contact PI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$791,956
UG3 · FY2021 · TR
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$536,333
R01 · FY2021 · DK · contact PI
Human Synthetic Liver Biology Core$188,407
P30 · FY2021 · DK · contact PI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$748,638
UG3 · FY2020 · TR
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$334,950
R01 · FY2017 · DK · contact PI
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$334,950
R01 · FY2016 · DK · contact PI
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$334,950
R01 · FY2015 · DK · contact PI
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy$327,388
R01 · FY2014 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$224,793
R00 · FY2013 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$232,946
R00 · FY2012 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$249,000
R00 · FY2011 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$90,000
K99 · FY2010 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$50,306
K99 · FY2009 · DK · contact PI
Engineering of hepatic grafts with decellularized native matrices$39,694
K99 · FY2009 · DK · contact PI